Clinical Trial

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-01-18; most recent amendment 2025-07-21.
Status change: Active, Not Recruiting → Recruiting 2025-07-21
Status change: Recruiting → Active, Not Recruiting 2025-03-23
Status change: Not Yet Recruiting → Recruiting 2023-05-28
Trial Details
NCT Number NCT05701709
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 395 participants
Start Date 2023-04-06
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-22